Search

Your search keyword '"Gumber, M. R."' showing total 102 results
Start Over Author "Gumber, M. R."
102 results on '"Gumber, M. R."'

1. The Effect of Stem Cell Transplantation on Immunosuppression in Living Donor Renal Transplantation: A Clinical Trial

Author

Trivedi, H. L., Vanikar, A. V., Kute, V. B., Patel, H. V., Gumber, M. R., Shah, P. R., Dave, S. D., and Trivedi, V. B.

Subjects
Clonal deletion, T-Lymphocytes, Graft rejection, Mesenchymal stem cells, Original Article, Renal transplantation, regulatory, Hematopoietic stem cells, Immunosuppression
Abstract

Background/Objective: We designed a clinical trial on a group of live-donor renal transplantation (LDRT) patients subjected to pre-transplant stem cell transplantation (SCT) to minimize immunosuppression to low-dose steroid monotherapy. Methods: LDRT patients subjected to pretransplant SCT who had stable graft function for ≥2 years and serum creatinine (SCr)

Published
2013

2. TRANSPLANTATION 2

Author

Orandi, B. J., primary, Kraus, E. S., additional, Bagnasco, S. M., additional, Van Arendonk, K. J., additional, Garonzik-Wang, J. M., additional, Wickliffe, C., additional, Montgomery, R. A., additional, Segev, D. L., additional, Trivedi, H. L., additional, Vanikar, A. V., additional, Dave, S. D., additional, Patel, H. V., additional, Kute, V. B., additional, Gumber, M. R., additional, Rawal, M. N., additional, Modi, P. R., additional, Rizvi, S. J., additional, Sicard, A., additional, Ducreux, S., additional, Rabeyrin, M., additional, McGregor, B., additional, Badet, L., additional, Scoazec, J.-Y., additional, Fremeau-Bacchi, V., additional, Morelon, E., additional, Dubois, V., additional, Thaunat, O., additional, Kiki ,  eljko, additional, Kainz, A., additional, Kozakowski, N., additional, Oberbauer, R., additional, Regele, H., additional, Bartel, G., additional, Boehmig, G. A., additional, Mallamaci, F., additional, Tripepi, R., additional, Leonardis, D., additional, Mafrica, A., additional, Versace, M. C., additional, Provenzano, F., additional, Tripepi, G., additional, and Zoccali, C., additional

Published
2014
Full Text
View/download PDF

3. TRANSPLANTATION CLINICAL 1

Author

Schachtner, T., primary, Reinke, P., additional, Dorje, C., additional, Mjoen, G., additional, Midtvedt, K., additional, Strom, E. H., additional, Oyen, O., additional, Jenssen, T., additional, Reisaeter, A. V., additional, Smedbraaten, Y. V., additional, Sagedal, S., additional, Fagerland, M. W., additional, Hartmann, A., additional, Thiel, S., additional, Zulkarnaev, A., additional, Vatazin, A., additional, Vincenti, F., additional, Harel, E., additional, Kantor, A., additional, Thurison, T., additional, Hoyer-Hansen, G., additional, Craik, C., additional, Kute, V. B., additional, Shah, P. S., additional, Vanikar, A. V., additional, Modi, P. R., additional, Shah, P. R., additional, Gumber, M. R., additional, Patel, H. V., additional, Engineer, D. P., additional, Shah, V. R., additional, Rizvi, J., additional, Trivedi, H. L., additional, Malheiro, J., additional, Dias, L., additional, Martins, L. S., additional, Fonseca, I., additional, Pedroso, S., additional, Almeida, M., additional, Castro-Henriques, A., additional, Cabrita, A., additional, Costa, C., additional, Ritta, M., additional, Sinesi, F., additional, Sidoti, F., additional, Mantovani, S., additional, Di Nauta, A., additional, Messina, M., additional, Cavallo, R., additional, Verflova, A., additional, Svobodova, E., additional, Slatinska, J., additional, Slavcev, A., additional, Pokorna, E., additional, Viklicky, O., additional, Yagan, J., additional, Chandraker, A., additional, Diena, D., additional, Tognarelli, G., additional, Ranghino, A., additional, Bussolino, S., additional, Fop, F., additional, Segoloni, G. P., additional, Biancone, L., additional, Leone, F., additional, Mauro, M. V., additional, Gigliotti, P., additional, Lofaro, D., additional, Greco, F., additional, Perugini, D., additional, Papalia, T., additional, Perri, A., additional, Vizza, D., additional, Giraldi, C., additional, Bonofilgio, R., additional, Luis-Lima, S., additional, Marrero, D., additional, Gonzalez-Rinne, A., additional, Torres, A., additional, Salido, E., additional, Jimenez-Sosa, A., additional, Aldea-Perona, A., additional, Gonzalez-Posada, J. M., additional, Perez-Tamajon, L., additional, Rodriguez-Hernandez, A., additional, Negrin-Mena, N., additional, Porrini, E., additional, Pihlstrom, H., additional, Dahle, D. O., additional, Holdaas, H., additional, Von Der Lippe, N., additional, Waldum, B., additional, Brekke, F., additional, Amro, A., additional, Os, I., additional, Klin, P., additional, Sanabria, H., additional, Bridoux, P., additional, De Francesco, J., additional, Fortunato, R. M., additional, Raffaele, P., additional, Kong, J., additional, Son, S. H., additional, Kwon, H. Y., additional, Whang, E. J., additional, Choi, W. Y., additional, Yoon, C. S., additional, Thanaraj, V., additional, Theakstone, A., additional, Stopper, K., additional, Ferraro, A., additional, Bhattacharjya, S., additional, Devonald, M., additional, Williams, A., additional, Mella, A., additional, Gallo, E., additional, Di Vico, M. C., additional, Pagani, F., additional, Gai, M., additional, Cho, H. J., additional, Nho, K. W., additional, Park, S.-K., additional, Kim, S. B., additional, Yoshida, K., additional, Ishii, D., additional, Ohyama, T., additional, Kohguchi, D., additional, Takeuchi, Y., additional, Varga, A., additional, Sandor, B., additional, Kalmar-Nagy, K., additional, Toth, A., additional, Toth, K., additional, Szakaly, P., additional, Kildushevsky, A., additional, Fedulkina, V., additional, Kantaria, R., additional, Staeck, O., additional, Halleck, F., additional, Rissling, O., additional, Naik, M., additional, Neumayer, H.-H., additional, Budde, K., additional, Khadzhynov, D., additional, Bhadauria, D., additional, Kaul, A., additional, Prasad, N., additional, Sharma, R. K., additional, Sezer, S., additional, Bal, Z., additional, Erkmen Uyar, M., additional, Guliyev, O., additional, Erdemir, B., additional, Colak, T., additional, Ozdemir, N., additional, Haberal, M., additional, Caliskan, Y., additional, Yazici, H., additional, Artan, A. S., additional, Oto, O. A., additional, Aysuna, N., additional, Bozfakioglu, S., additional, Turkmen, A., additional, Yildiz, A., additional, Sever, M. S., additional, Yagisawa, T., additional, Nukui, A., additional, Kimura, T., additional, Nannmoku, K., additional, Kurosawa, A., additional, Sakuma, Y., additional, Miki, A., additional, Damiano, F., additional, Ligabue, G., additional, De Biasi, S., additional, Granito, M., additional, Cossarizza, A., additional, Cappelli, G., additional, Henriques, A. C., additional, Davide, J., additional, Von During, M. E., additional, Jenssen, T. G., additional, Bollerslev, J., additional, Godang, K., additional, Asberg, A., additional, Bachelet, T., additional, Martinez, C., additional, Bello, A., additional, Kejji, S., additional, Couzi, L., additional, Guidicelli, G., additional, Lepreux, S., additional, Visentin, J., additional, Congy-Jolivet, N., additional, Rostaing, L., additional, Taupin, J.-L., additional, Kamar, N., additional, Merville, P., additional, Ozdemir, H., additional, Yildirim, S., additional, Tutal, E., additional, Sayin, B., additional, Ozdemir Acar, N., additional, Banasik, M., additional, Boratynska, M., additional, Koscielska-Kasprzak, K., additional, Kaminska, D., additional, Bartoszek, D., additional, Mazanowska, O., additional, Krajewska, M., additional, Zmonarski, S., additional, Chudoba, P., additional, Dawiskiba, T., additional, Protasiewicz, M., additional, Halon, A., additional, Sas, A., additional, Kaminska, M., additional, Klinger, M., additional, Stefanovic, N., additional, Cvetkovic, T., additional, Velickovic - Radovanovic, R., additional, Jevtovic - Stoimenov, T., additional, Vlahovic, P., additional, Rungta, R., additional, Das, P., additional, Ray, D. S., additional, Gupta, S., additional, Kolonko, A., additional, Szotowska, M., additional, Kuczera, P., additional, Chudek, J., additional, Wiecek, A., additional, Sikora-Grabka, E., additional, Adamczak, M., additional, Madej, P., additional, Amanova, A., additional, Kendi Celebi, Z., additional, Bakar, F., additional, Caglayan, M. G., additional, Keven, K., additional, Massimetti, C., additional, Imperato, G., additional, Zampi, G., additional, De Vincenzi, A., additional, Fabbri, G. D. D., additional, Brescia, F., additional, Feriozzi, S., additional, Filipov, J. J., additional, Zlatkov, B. K., additional, Dimitrov, E. P., additional, Svinarov, D. A., additional, Poesen, R., additional, De Vusser, K., additional, Evenepoel, P., additional, Kuypers, D., additional, Naesens, M., additional, Meijers, B., additional, Kocak, H., additional, Yilmaz, V. T., additional, Yilmaz, F., additional, Uslu, H. B., additional, Aliosmanoglu, I., additional, Ermis, H., additional, Dinckan, A., additional, Cetinkaya, R., additional, Ersoy, F. F., additional, Suleymanlar, G., additional, Oliveira, J.-C., additional, Santos, J., additional, Lobato, L., additional, Mendonca, D., additional, Watarai, Y., additional, Yamamoto, T., additional, Tsujita, M., additional, Hiramitsu, T., additional, Goto, N., additional, Narumi, S., additional, Kobayashi, T., additional, Line, P.-D., additional, Housawi, A., additional, House, A., additional, Ng, C., additional, Denesyk, K., additional, Rehman, F., additional, Moist, L., additional, Musetti, C., additional, Battista, M., additional, Izzo, C., additional, Guglielmetti, G., additional, Airoldi, A., additional, Stratta, P., additional, Cena, T., additional, Quaglia, M., additional, Fenoglio, R., additional, Cagna, D., additional, Amoroso, A., additional, Palmisano, A., additional, Degli Antoni, A. M., additional, Vaglio, A., additional, Piotti, G., additional, Cremaschi, E., additional, Buzio, C., additional, Maggiore, U., additional, Lee, M.-C., additional, Hsu, B.-G., additional, Zalamea Jarrin, F., additional, Sanchez Sobrino, B., additional, Lafuente Covarrubias, O., additional, Karsten Alvarez, S., additional, Dominguez Apinaniz, P., additional, Llopez Carratala, R., additional, Portoles Perez, J., additional, Yildirim, T., additional, Yilmaz, R., additional, Turkmen, E., additional, Altindal, M., additional, Arici, M., additional, Altun, B., additional, Erdem, Y., additional, Dounousi, E., additional, Mitsis, M., additional, Naka, K., additional, Pappas, H., additional, Lakkas, L., additional, Harisis, H., additional, Pappas, K., additional, Koutlas, V., additional, Tzalavra, I., additional, Spanos, G., additional, Michalis, L., additional, Siamopoulos, K., additional, Iwabuchi, T., additional, Nanmoku, K., additional, Yasunaru, S., additional, Yoshikawa, M., additional, Kitamura, K., additional, Fuji, H., additional, Fujisawa, M., additional, Nishi, S., additional, Carta, P., additional, Zanazzi, M., additional, Buti, E., additional, Larti, A., additional, Caroti, L., additional, Di Maria, L., additional, Minetti, E. E., additional, Shi, Y., additional, Luo, L., additional, Cai, B., additional, Wang, T., additional, Zou, Y., additional, Wang, L., additional, Kim, Y., additional, Kim, H. S., additional, Choi, B. S., additional, Park, C. W., additional, Yang, C. W., additional, Kim, Y.-S., additional, Chung, B. H., additional, Baek, C. H., additional, Kim, M., additional, Kim, J.-S., additional, Yang, W. S., additional, Han, D. J., additional, Mikolasevic, I., additional, Racki, S., additional, Lukenda, V., additional, Persic, M. P., additional, Colic, M., additional, Devcic, B., additional, Orlic, L., additional, Gurlek Demirci, B., additional, Say N, C. B., additional, Ozdemir Acar, F. N., additional, Vali, S., additional, Ismal, K., additional, Sahay, M., additional, Civiletti, F., additional, Cantaluppi, V., additional, Medica, D., additional, Mazzeo, A. T., additional, Assenzio, B., additional, Mastromauro, I., additional, Deambrosis, I., additional, Giaretta, F., additional, Fanelli, V., additional, Mascia, L., additional, Gkirdis, I., additional, Bechlioulis, A., additional, Evangelou, D., additional, Zarzoulas, F., additional, Kotsia, A., additional, Balafa, O., additional, Tzeltzes, G., additional, Nakas, G., additional, Kalaitzidis, R., additional, Katsouras, C., additional, Uyanik, S., additional, Toprak, S. K., additional, Ilhan, O., additional, Ekmen Uyar, M., additional, Hernandez Vargas, H., additional, Artamendi Larranaga, M., additional, Ramalle Gomara, E., additional, Gil Catalinas, F., additional, Bello Ovalle, A., additional, Pimentel Guzman, G., additional, Coloma Lopez, A., additional, Sierra Carpio, M., additional, Gil Paraiso, A., additional, Dall Anesse, C., additional, Beired Val, I., additional, Huarte Loza, E., additional, Choy, B. Y., additional, Kwan, L., additional, Mok, M., additional, Chan, T. M., additional, Yamakawa, T., additional, Kobayashi, A., additional, Yamamoto, I., additional, Mafune, A., additional, Nakada, Y., additional, Tannno, Y., additional, Tsuboi, N., additional, Yamamoto, H., additional, Yokoyama, K., additional, Ohkido, I., additional, Yokoo, T., additional, Luque, Y., additional, Anglicheau, D., additional, Rabant, M., additional, Clement, R., additional, Kreis, H., additional, Sartorius, A., additional, Noel, L.-H., additional, Timsit, M.-O., additional, Legendre, C., additional, Rancic, N., additional, Vavic, N., additional, Dragojevic-Simic, V., additional, Katic, J., additional, Jacimovic, N., additional, Kovacevic, A., additional, Mikov, M., additional, Veldhuijzen, N. M. H., additional, Rookmaaker, M. B., additional, Van Zuilen, A. D., additional, Nquyen, T. Q., additional, Boer, W. H., additional, Sahtout, W., additional, Ghezaiel, H., additional, Azzebi, A., additional, Ben Abdelkrim, S., additional, Guedri, Y., additional, Mrabet, S., additional, Nouira, S., additional, Ferdaws, S., additional, Amor, S., additional, Belarbia, A., additional, Zellama, D., additional, Mokni, M., additional, Achour, A., additional, Parikova, A., additional, Hanzal, V., additional, Fronek, J., additional, Orandi, B. J., additional, James, N. T., additional, Montgomery, R. A., additional, Desai, N. M., additional, Segev, D. L., additional, Fontana, F., additional, Ballestri, M., additional, and Magistroni, R., additional

Published
2014
Full Text
View/download PDF

4. Transplantation - clinical studies II

Author

Marques, I. B., primary, Silva, R. d. M., additional, Moraes, C. E., additional, Azevedo, L. S., additional, Nahas, W. C., additional, David-Neto, E., additional, Furmanczyk-Zawiska, A., additional, Baczkowska, T., additional, Chmura, A., additional, Szmidt, J., additional, Durlik, M., additional, Joslin, J., additional, Blaker, P., additional, White, B., additional, Marinaki, A., additional, Sanderson, J., additional, Goldsmith, D. J., additional, Medani, S., additional, Traynor, C., additional, Mohan, P., additional, Little, D., additional, Conlon, P., additional, Molina, M., additional, Gonzalez, E., additional, Gutierrez, E., additional, Sevillano, A., additional, Polanco, N., additional, Morales, E., additional, Hernandez, A., additional, Praga, M., additional, Morales, J. M., additional, Andres, A., additional, Park, S. J., additional, Kim, T. H., additional, Kim, Y. W., additional, Kim, Y. H., additional, Kang, S. W., additional, Kujawa-Szewieczek, A., additional, Szotowska, M., additional, Kuczera, P., additional, Chudek, J., additional, Wiecek, A., additional, Kolonko, A., additional, Mahrova, A., additional, Svagrova, K., additional, Bunc, V., additional, Stollova, M., additional, Teplan, V., additional, Hundt, F., additional, van Heteren, P., additional, Woitas, R., additional, Cavallo, M. C., additional, Sepe, V., additional, Conte, F., additional, Albrizio, P., additional, Bottazzi, A., additional, Geraci, P. M., additional, Alpay, N., additional, Gumber, M. R., additional, Kute, V. B., additional, Vanikar, A. V., additional, Patel, H. V., additional, Shah, P. R., additional, Engineer, D. P., additional, Trivedi, H. L., additional, Golebiewska, J. E., additional, Debska-Slizien, A., additional, Rutkowski, B., additional, Matias, P., additional, Martins, A. R., additional, Raposo, L., additional, Jorge, C., additional, Weigert, A., additional, Birne, R., additional, Bruges, M., additional, Adragao, T., additional, Almeida, M., additional, Mendes, M., additional, Machado, D., additional, Masin-Spasovska, J., additional, Dohcev, S., additional, Stankov, O., additional, Stavridis, S., additional, Saidi, S., additional, Dejanova, B., additional, Rambabova-Busletic, I., additional, Dejanov, P., additional, Spasovski, G., additional, Nho, K. W., additional, Han, D. J., additional, Park, S.-K., additional, Kim, S. B., additional, Fenoglio, R., additional, Lazzarich, E. E., additional, Cagna, D., additional, Cena, T., additional, Conti, N., additional, Quaglia, M., additional, Radin, E., additional, Izzo, C., additional, Stratta, P., additional, Oh, I. H., additional, Park, J.-S., additional, Lee, C. H., additional, Kang, C. M., additional, Kim, G.-H., additional, Leone, F., additional, Lofaro, D., additional, Gigliotti, P., additional, Lupinacci, S., additional, Toteda, P., additional, Vizza, D., additional, Perri, A., additional, Papalia, T., additional, Bonofiglio, R., additional, di Loreto, P., additional, de Silvestro, L., additional, Montanaro, D., additional, Martino, F., additional, Sandrini, S., additional, Minetti, E., additional, Cabiddu, G., additional, Yildirim, T., additional, Yilmaz, R., additional, Turkmen, E., additional, Abudalal, A., additional, Altindal, M., additional, Ertoy-Baydar, D., additional, Erdem, Y., additional, Panuccio, V., additional, Tripepi, R., additional, Parlongo, G., additional, Versace, M. C., additional, Politi, R., additional, Zoccali, C., additional, Mallamaci, F., additional, Porrini, E., additional, Silva, I., additional, Diaz, J., additional, Ibernon, M., additional, Moreso, F., additional, Benitez, R., additional, Delgado Mallen, P., additional, Osorio, J., additional, Lauzurica, R., additional, Torres, A., additional, Ersoy, A., additional, Koca, N., additional, Gullu Koca, T., additional, Kirhan, E., additional, Sarandol, E., additional, Ersoy, C., additional, Dirican, M., additional, Milne, J., additional, Suter, V., additional, Mikhail, A., additional, Akalin, H., additional, Dizdar, O., additional, Pascual, J., additional, Torio, A., additional, Garcia, C., additional, Hernandez, J., additional, Perez-Saez, M. J., additional, Mir, M., additional, Anna, F., additional, Crespo, M., additional, Carta, P., additional, Zanazzi, M., additional, Antognoli, G., additional, Di Maria, L., additional, Caroti, L., additional, Ray, D. S., additional, Mukherjee, K., additional, Bohidar, N. P., additional, Pattanaik, A., additional, Das, P., additional, Thukral, S., additional, Kimura, T., additional, Yagisawa, T., additional, Ishikawa, N., additional, Sakuma, Y., additional, Fujiwara, T., additional, Nukui, A., additional, Gavela, E. E., additional, Sancho, A. A., additional, Kanter, J. J., additional, Avila, A. A., additional, Beltran, S. S., additional, Pallardo, L. L., additional, Dawoud, F. G., additional, Aithal, V., additional, Majernikova, M., additional, Rosenberger, J., additional, Prihodova, L., additional, Nagyova, I., additional, Jarcuskova, M., additional, Roland, R., additional, Groothoff, J. W., additional, van Dijk, J. P., additional, van Agteren, M., additional, de Weerd, A., additional, van de Wetering, J., additional, IJzermans, J., additional, Betjes, M., additional, Weimar, W., additional, Popoola, J., additional, Reed, A., additional, Tavarro, R., additional, Chryssanthopoulou, C., additional, MacPhee, I., additional, Mayor, M., additional, Franco, S., additional, Jara, P., additional, Ayala, R., additional, Orue, M. G., additional, Martinez, A., additional, Martinez, M., additional, Wasmouth, N., additional, Arik, G., additional, Yasar, A., additional, Yilmaz, S., additional, Arici, M., additional, Bihari Bansal, S., additional, Pokhariyal, S., additional, Jain, S., additional, Sethi, S., additional, Ahlawat, R., additional, Kher, V., additional, Martins, L. S., additional, Aguiar, P., additional, Dias, L., additional, Fonseca, I., additional, Henriques, A. C., additional, Cabrita, A., additional, Davide, J., additional, Sparkes, T. M., additional, Trofe-Clark, J., additional, Reese, P. P., additional, Jakobowski, D., additional, Goral, S., additional, Doll, S. L., additional, Abt, P. L., additional, Sawinski, D., additional, MBloom, R. D., additional, Knap, B., additional, Lukac, J., additional, Lukin, M., additional, Majcen, I., additional, Pavlovec, F., additional, Kandus, A., additional, Bren, A. F., additional, Kong, J. M., additional, Jeong, J. H., additional, Ahn, J., additional, Lee, D. R., additional, Son, S. H., additional, Kim, B. C., additional, Choi, W. Y., additional, Whang, E. J., additional, Czajka, B., additional, Malgorzewicz, S., additional, Panizo, N., additional, Rengel, M. A., additional, Vega, A., additional, Abad, S., additional, Tana, L., additional, Arroyo, D., additional, Rodriguez-Ferrero, M., additional, Perez de Jose, A., additional, Lopez-Gomez, J. M., additional, Koutroutsos, K., additional, Sackey, J., additional, Paolini, L., additional, Ramkhelawon, R., additional, Chowrimootoo, M., additional, Whelan, D., additional, Slatinska, J., additional, Honsova, E., additional, Wohlfahrtova, M., additional, Slimackova, E., additional, Rajnochova, S. B., additional, Viklicky, O., additional, Yankovoy, A., additional, Smith, I. S. J., additional, Wylie, E., additional, Ruiz-Esteban, P., additional, Lopez, V., additional, Garcia-Frias, P., additional, Cabello, M., additional, Gonzalez-Molina, M., additional, Vozmediano, C., additional, Hernandez, D., additional, Pavlovic, J., additional, Radivojevic, D., additional, Lezaic, V., additional, Simic-Ogrizovic, S., additional, Lausevic, M., additional, Naumovic, R., additional, Sakhuja, V., additional, Gundlapalli, S., additional, Rathi, M., additional, Jha, V., additional, Kohli, H. S., additional, Sharma, A., additional, Minz, M., additional, Nimgirova, A., additional, Esayan, A., additional, Kayukov, I., additional, Zuyeva, E., additional, Bilen, Y., additional, Cankaya, E., additional, Keles, M., additional, Gulcan, E., additional, Turkeli, M., additional, Albayrak, B., additional, Uyanik, A., additional, Yildirim, R., additional, Molitor, N., additional, Praktiknjo, M., additional, Abeygunaratne, T. N., additional, Balasubramanian, S., additional, Baker, R., additional, Nicholson, T., additional, Toprak, O., additional, Sari, Y., additional, Keceli, S., additional, Kurt, H., additional, Rocha, A., additional, Malheiro, J., additional, Pedroso, S., additional, Henriques, A., additional, Nihei, C., additional, Bacelar Marques, I., additional, Seguro, C. A., additional, Mate, G., additional, Martin, N., additional, Colon, L., additional, Casellas, L., additional, Garangou, D., additional, de la Torre, M., additional, Torguet, P., additional, Garcia, I., additional, Calabia, J., additional, Valles, M., additional, Pruthi, R., additional, Calestani, M., additional, Leydon, G., additional, Ravanan, R., additional, Roderick, P., additional, Korkmaz, S., additional, and Gulten, S., additional

Published
2013
Full Text
View/download PDF

7. Specrtum of Post Transplant Bone Disorder

Author

Patel, M. P., primary, Trivedi, H. L., additional, Jain, S. H., additional, Kute, V. B., additional, Gumber, M. R., additional, Shah, P. R., additional, Patel, H. V., additional, Vanikar, A. V., additional, and Sainaresh, V. V., additional

Published
2012
Full Text
View/download PDF

13. Transplantation: basic science and immune-tolerance

Author

Sugawara, M., primary, Ichimura, S., additional, Kokubo, K., additional, Shimbo, T., additional, Hirose, M., additional, Kobayashi, H., additional, Hribova, P., additional, Brabcova, I., additional, Honsova, E., additional, Viklicky, O., additional, Kute, V. B., additional, Shah, P. R., additional, Vanikar, A. V., additional, Gumber, M. R., additional, Patel, H. V., additional, Modi, P. R., additional, Trivedi, H. L., additional, Trivedi, V. B., additional, Nusrath, S., additional, Minz, M., additional, Walker Minz, R., additional, Sharma, A., additional, Singh, S., additional, Jha, V., additional, Joshi, K., additional, Richter, R., additional, Kohler, S., additional, Qidan, S., additional, Scheuermann, E., additional, Kachel, H.-G., additional, Gossmann, J., additional, Gauer, S., additional, Seifried, E., additional, Geiger, H., additional, Seidl, C., additional, Hauser, I. A., additional, Hanssen, L., additional, Frye, B., additional, Ostendorf, T., additional, Alidousty, C., additional, Djudjaj, S., additional, Boor, P., additional, Rauen, T., additional, Floege, J., additional, Mertens, P., additional, Raffetseder, U., additional, Garcia-Cenador, B., additional, Lopez-Novoa, J. M., additional, Iniguez, M., additional, Fernandez, V., additional, Perez de Obanos, P., additional, Ruiz, J., additional, Sanz-Gimenez, J. R., additional, Lopez-Marcos, J. F., additional, Garcia-Criado, J., additional, Van Craenenbroeck, A. H., additional, Anguille, S. H., additional, Jurgens, A., additional, Cools, N., additional, Van Camp, K., additional, Stein, B., additional, Nijs, G., additional, Berneman, Z., additional, Ieven, M., additional, Van Damme, P., additional, Van Tendeloo, V., additional, Verpooten, G. A., additional, Gohel, K., additional, Hegde, U., additional, Gang, S., additional, Rajapurkar, M., additional, Erdogmus, S., additional, Sengul, S., additional, Kocak, S., additional, Kurultak, I., additional, Kutlay, S., additional, Keven, K., additional, Erbay, B., additional, Erturk, S., additional, Kimura, S., additional, Imura, J., additional, Atsumi, H., additional, Fujimoto, K., additional, Chikazawa, Y., additional, Nakagawa, M., additional, Hayama, T., additional, Okuyama, H., additional, Yamaya, H., additional, Yokoyama, H., additional, Libetta, C., additional, Canevari, M., additional, Sepe, V., additional, Margiotta, E., additional, Meloni, F., additional, Martinelli, C., additional, Borettaz, I., additional, Esposito, P., additional, Portalupi, V., additional, Morosini, M., additional, Solari, N., additional, Dal Canton, A., additional, Rusai, K., additional, Schmaderer, C., additional, Hermans, R., additional, Lutz, J., additional, Heemann, U., additional, Baumann, M., additional, Cantaluppi, V., additional, Tamagnone, M., additional, Dellepiane, S., additional, Medica, D., additional, Dolla, C., additional, Messina, M., additional, Manzione, A. M., additional, Tognarelli, G., additional, Ranghino, A., additional, Biancone, L., additional, Camussi, G., additional, Segoloni, G. P., additional, Ozkurt, S., additional, Sahin, G., additional, Degirmenci, N., additional, Temiz, G., additional, Musmul, A., additional, Birdane, A., additional, Tek, M., additional, Tekin, N., additional, Akyuz, F., additional, Yalcin, A. U., additional, and Lopez-Valverde, A., additional

Published
2011
Full Text
View/download PDF

14. Acute kidney injury - Human studies

Author

Locsey, L., primary, Seres, I., additional, Sztanek, F., additional, Harangi, M., additional, Padra, J., additional, Asztalos, L., additional, Paragh, G., additional, Hutchison, C. A., additional, Bevins, A., additional, Langham, R., additional, Mancini, E., additional, Wirta, O., additional, Cockwell, P., additional, Keir, R., additional, Vigano, M., additional, Stella, A., additional, Evans, N., additional, Chappell, M., additional, Fabbrini, P., additional, Onuigbo, M., additional, Onuigbo, N., additional, Kim, S., additional, Chang, J. H., additional, Jung, J. Y., additional, Lee, H. H., additional, Chung, W., additional, Zanoli, L., additional, Rastelli, S., additional, Marcantoni, C., additional, Tamburino, C., additional, Castellino, P., additional, Cho, A., additional, Choi, H., additional, Lee, J. E., additional, Jang, H. R., additional, Huh, W., additional, Kim, Y.-G., additional, Kim, D. J., additional, Oh, H. Y., additional, Garcia-Fernandez, N., additional, Martin-Moreno, P. L., additional, Varo, N., additional, Nunez-Cordoba, J. M., additional, Schlieper, G., additional, Kruger, T., additional, Kelm, M., additional, Floege, J., additional, Westenfeld, R., additional, Cho, A. J., additional, Doganay, S., additional, Oguz, A. K., additional, Ergun, I., additional, Bardachenko, N., additional, Kuryata, O., additional, Bardachenko, L., additional, Ravani, P., additional, Malberti, F., additional, Pirelli, S., additional, Scolari, F., additional, Barrett, B., additional, Presta, P., additional, Lucisano, G., additional, Rubino, A., additional, Serraino, F., additional, Amoruso, T., additional, Renzulli, A., additional, Fuiano, G., additional, Kielstein, J. T., additional, Tolk, S., additional, Heiden, A., additional, Kuhn, C., additional, Hoeper, M. M., additional, Lorenzen, J., additional, Broll, M., additional, Kaever, V., additional, Burhenne, H., additional, Hafer, C., additional, Haller, H., additional, Burkhardt, O., additional, Kielstein, J., additional, Zahalkova, J., additional, Petejova, N., additional, Strojil, J., additional, Urbanek, K., additional, Bertoli, S., additional, Musetti, C., additional, Cabiati, A., additional, Assanelli, E., additional, Lauri, G., additional, Marana, I., additional, De Metrio, M., additional, Rubino, M., additional, Campodonico, J., additional, Grazi, M., additional, Moltrasio, M., additional, Marenzi, G., additional, Unarokov, Z., additional, Mukhoedova, T., additional, Fidalgo, P., additional, Coelho, S., additional, Rodrigues, B., additional, Fernandes, A. P., additional, Papoila, A. L., additional, Liano, F., additional, Soto, K., additional, Vanmassenhove, J., additional, Vanholder, R., additional, Glorieux, G., additional, Van Biesen, W., additional, Challiner, R., additional, Ritchie, J., additional, Hutchison, A., additional, Zaharie, S. I., additional, Maria, D. T., additional, Zaharie, M., additional, Vaduva, C., additional, Grauntanu, C., additional, Cana-Ruiu, D., additional, Mota, E., additional, Hayer, M., additional, Baharani, J., additional, Thomas, M., additional, Eldehni, T., additional, Selby, N., additional, McIntyre, C., additional, Fluck, R., additional, Kolhe, N., additional, Fagugli, R. M., additional, Patera, F., additional, Shah, P. R., additional, Kaswan, K. K., additional, Kute, V. B., additional, Vanikar, A. V., additional, Gumber, M. R., additional, Patel, H. V., additional, Munjappa, B. C., additional, Enginner, D. P., additional, Sainaresh, V. V., additional, Trivedi, H. L., additional, Teixeira, C., additional, Nogueira, E., additional, Lopes, J. A., additional, Almeida, E., additional, Pais de Lacerda, A., additional, Gomes da Costa, A., additional, Franca, C., additional, Mariano, F., additional, Morselli, M., additional, Bergamo, D., additional, Hollo', Z., additional, Scella, S., additional, Maio, M., additional, Tetta, C., additional, Dellavalle, A., additional, Stella, M., additional, Triolo, G., additional, Cantaluppi, V., additional, Quercia, A. D., additional, Bertinetto, P., additional, Giacalone, S., additional, Tamagnone, M., additional, Basso, E., additional, Karvela, E., additional, Gai, M., additional, Leonardi, G., additional, Anania, P., additional, Guarena, C., additional, Fenocchio, C. M., additional, Pacitti, A., additional, Segoloni, G. P., additional, Kim, Y. O., additional, Kim, H. G., additional, Kim, B. S., additional, Song, H. C. S., additional, Min, J.-K., additional, Kim, S. Y., additional, Park, W. D., additional, Dalboni, M., additional, Narciso, R., additional, Quinto, M., additional, Grabulosa, C., additional, Cruz, E., additional, Monte, J., additional, Durao, M., additional, Cendoroglo, M., additional, Santos, O., additional, Batista, M., additional, Bellasi, A., additional, Giannone, S., additional, Mordenti, A., additional, Zanoni, A., additional, Santoro, A., additional, Lee, J. H., additional, Ha, S. H., additional, Kim, J. H., additional, Lee, G. J., additional, Jung, Y. C., additional, Malindretos, P., additional, Koutroumbas, G., additional, Patrinou, A., additional, Zagkotsis, G., additional, Makri, P., additional, Togousidis, I., additional, Syrganis, C., additional, Li Cavoli, G., additional, Tortorici, C., additional, Bono, L., additional, Ferrantelli, A., additional, Giammarresi, C., additional, Zagarrigo, C., additional, Rotolo, U., additional, Kim, H., additional, Jun, K., additional, Choi, W., additional, Krzesinski, J.-M., additional, Parotte, M.-C., additional, Vandevelde, C., additional, Keenan, J., additional, Dieterle, F., additional, Sultana, S., additional, Pinches, M., additional, Ciorciaro, C., additional, Schindler, R., additional, Schmitz, V., additional, Gautier, J.-C., additional, Benain, X., additional, Matchem, J., additional, Murray, P., additional, Adler, S., additional, Haase, M., additional, Haase-Fielitz, A., additional, Devarajan, P., additional, Bellomo, R., additional, Cruz, D. N., additional, Wagener, G., additional, Krawczeski, C. D., additional, Koyner, J. L., additional, Murray, P. T., additional, Zappitelli, M., additional, Goldstein, S., additional, Makris, K., additional, Ronco, C., additional, Martensson, J., additional, Martling, C.-R., additional, Venge, P., additional, Siew, E., additional, Ware, L. B., additional, Ikizler, A., additional, Mertens, P. R., additional, Lacquaniti, A., additional, Buemi, A., additional, Donato, V., additional, Lucisano, S., additional, Buemi, M., additional, Panagoutsos, S., additional, Kriki, P., additional, Mourvati, E., additional, Tziakas, D., additional, Chalikias, G., additional, Stakos, D., additional, Apostolakis, S., additional, Tsigalou, C., additional, Gioka, T., additional, Konstantinides, S., additional, Vargemezis, V., additional, Torregrosa, I., additional, Montoliu, C., additional, Urios, A., additional, Aguado, C., additional, Puchades, M. J., additional, Solis, M. A., additional, Juan, I., additional, Sanjuan, R., additional, Blasco, M., additional, Pineda, J., additional, Carratala, A., additional, Ramos, C., additional, Miguel, A., additional, Niculae, A., additional, Checherita, I. A., additional, Sandulovici, R., additional, David, C., additional, Ciocalteu, A., additional, Espinoza, M., additional, Hidalgo, J., additional, Lorca, E., additional, Santibanez, A., additional, Arancibia, F., additional, Gonzalez, F., additional, Park, M. Y., additional, Kim, E. J., additional, Choi, S. J., additional, Kim, J. K., additional, Hwang, S. D., additional, Lee, K.-h., additional, Seok, S.-J., additional, Yang, J.-O., additional, Lee, E.-Y., additional, Hong, S.-y., additional, Gil, H.-w., additional, Astapenko, E., additional, Shutov, A., additional, Savinova, G., additional, Rechnik, V., additional, Melo, M. J., additional, Raimundo, M., additional, Viegas, A., additional, Camara, I., additional, Antunes, F., additional, Kim, M.-J., additional, Kwon, S. H., additional, Lee, S. W., additional, Song, J. H., additional, and Lee, J. W., additional

Published
2011
Full Text
View/download PDF

18. Outcome of live and deceased donor renal transplantation in patients aged ≥55 years: A single.center experience.

Author

Kute, V. B., Vanikar, A. V., Shah, P. R., Gumber, M. R., Patel, H. V., Modi, P. R., Rizvi, S. J., Shah, V. R., Modi, M. P., Kanodia, K. V., and Trivedi, H. L.

Subjects
CHRONIC kidney failure, ACADEMIC medical centers, CHI-squared test, COMPARATIVE studies, DEAD, FISHER exact test, KIDNEY transplantation, ORGAN donors, HEALTH outcome assessment, SURVIVAL, T-test (Statistics), TREATMENT effectiveness, DATA analysis software, DESCRIPTIVE statistics, KAPLAN-Meier estimator, LOG-rank test, SURGERY
Abstract

Renal transplantation (RTx) has now become an accepted therapeutic modality of choice for elderly ESRD patients. This single-center study was undertaken to evaluate the outcome of RTx in ESRD patients. ≥5 years. A total of 103 patients underwent RTx 79 living related living donors [LD], 24 deceased donors [DD]) at our center. Post-transplant immunosuppression consisted of calcineurin inhibitor-based regimen. The mean donor age was 58.3 years in the LD group and 59.5 years in the DD group. Male recipients constituted 92% in LD and 75% in DD group. In living donor renal transplantation, 1- and 5-year patient survival was 93% and 83.3% respectively and death-censored graft survival was 97.3% and 92.5% respectively. There were 12.6% biopsy proven acute rejection (BPAR) episodes and 12.6% patients were lost, mainly due to infections. In deceased donor renal transplantation, 1- and 5-year patient survival was 79.1% and 74.5% respectively and death-censored graft survival was 95.8% and 85.1% respectively. There were 12.5% BPAR episodes and 25% of patients were lost, mainly due to infections. RTx in ESRD (≥55 years) patients has acceptable patient and graft survival if found to have cardiac fitness and therefore should be encouraged. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

20. Successful renal transplantation from a brain.dead deceased donor with head injury, disseminated intravascular coagulation and deranged renal functions.

Author

Ghuge, P. P., Kute, V. B., Vanikar, A. V., Gumber, M. R., Gera, D. N., Patel, H. V., Shah, P. R., Modi, P. R., Shah, V. R, and Trivedi, H. L.

Subjects
ACADEMIC medical centers, BLOOD testing, BRAIN death, DISSEMINATED intravascular coagulation, KIDNEY transplantation, CASE studies, DESCRIPTIVE statistics
Abstract

Deceased donors (DDs) with the brain death due to head injury are the major source of organs for transplantation. The incidence of post-head injury disseminated intravascular coagulation (DIC) ranges from 24% to 50%. Many centers do not accept organs from donors with DIC due to increased risk of primary graft non-function and/or high chances of morbidity/mortality. We performed two successful renal transplants from a DD with head injury with DIC and deranged renal function. One of the recipients developed transient thrombocytopenia, but there was no evidence of DIC or delayed graft functions in either of the recipients. Over a follow-up of 1 month, both are doing well with stable graft function and hematological profile. Thus, a carefully selected DD with severe DIC even with deranged renal function is not a contraindication for organ donation if other risk factors for primary non-function are excluded. This approach will also help in overcoming organ shortage. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

22. Outcome and prognostic factors of malaria-associated acute kidney injury requiring hemodialysis: A single center experience.

Author

Kute, V. B., Shah, P. R., Munjappa, B. C., Gumber, M. R., Patel, H. V., Jain, S. H., Engineer, D. P., Sai Naresh, V. V., Vanikar, A. V., and Trivedi, H. L.

Subjects
KIDNEY failure, ANALYSIS of variance, APACHE (Disease classification system), BLOOD testing, COMA, CONFIDENCE intervals, DIALYSIS (Chemistry), LONGITUDINAL method, MALARIA, MULTIVARIATE analysis, HEALTH outcome assessment, SCALES (Weighing instruments), STATISTICS, U-statistics, DATA analysis, TREATMENT effectiveness, SEVERITY of illness index, DATA analysis software, THERAPEUTICS
Abstract

Acute kidney injury (AKI) is one of the most dreaded complications of severe malaria. We carried out prospective study in 2010, to describe clinical characteristics, laboratory parameters, prognostic factors, and outcome in 59 (44 males, 15 females) smear-positive malaria patients with AKI. The severity of illness was assessed using Acute Physiology and Chronic Health Evaluation (APACHE) II, Sequential Organ Failure Assessment (SOFA) score, Multiple Organ Dysfunction Score (MODS), and Glasgow Coma Scale (GCS) scores. All patients received artesunate and hemodialysis (HD). Mean age of patients was 33.63 ± 14 years. Plasmodium falciparum malaria was seen in 76.3% (n = 45), Plasmodium vivax in 16.9% (n = 10), and mixed infection in 6.8% (n = 4) patients. Presenting clinical features were fever (100%), nausea-vomiting (85%), oliguria (61%), abdominal pain/tenderness (50.8%), and jaundice (74.5%). Mean APACHE II, SOFA, MODS, and GCS scores were 18.1 ± 3, 10.16 ± 3.09, 9.71 ± 2.69, and 14.15 ± 1.67, respectively, all were higher among patients who died than among those who survived. APACHE II ≥20, SOFA and MODS scores ≥12 were associated with higher mortality (P < 0.05). 34% patients received blood component transfusion and exchange transfusion was done in 15%. Mean number of HD sessions required was 4.59 ± 3.03. Renal biopsies were performed in five patients (three with patchy cortical necrosis and two with acute tubular necrosis). 81.3% of patients had complete renal recovery and 11.8% succumbed to malaria. Prompt diagnosis, timely HD, and supportive therapy were associated with improved survival and recovery of kidney functions in malarial with AKI. Mortality was associated with higher APACHE II, SOFA, MODS, GCS scores, requirement of inotrope, and ventilator support. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

24. Deceased donor organ transplantation: A single center experience.

Author

Gumber, M. R., Kute, V. B., Goplani, K. R., Shah, P. R., Patel, H. V., Vanikar, A. V., Modi, P. R., and Trivedi, H. L.

Subjects
*CHRONIC kidney failure, *DEATH, *IMMUNOSUPPRESSIVE agents, *KIDNEY transplantation, *ORGAN donors, *RETROSPECTIVE studies
Abstract

Renal transplantation (RTx) is the best therapeutic modality for patient suffering from end-stage renal disease (ESRD). Deceased donor organ transplantation (DDOT) accounts for <4% of RTx in India. We report 4 years single centre experience on DDOT vis-à-vis patient/graft survival, graft function in terms of serum creatinine (SCr), rejection episodes, and delayed graft function in 160 DDOT. Between January 2006 to December 2009, 160 RTx from 89 donors were performed, of which 25.2% were expanded criteria donors. Majority of the donors were brain dead due to road traffic/cerebrovascular accidents. The commonest recipient diseases leading to ESRD were chronic glomerulonephritis (49%), diabetes mellitus (10%), and benign nephrosclerosis (10%). Mean recipient/donor age was 35.6±14.68 and 44.03±18.19 years. Mean dialysis duration pretransplantation was 15.37±2.82 months. Mean cold ischemia time was 5.56±2.04 hours. All recipients received single dose rabbit-anti-thymocyte globulin induction and steroids, mycophenolate mofetil/calcinueurin inhibitor for maintenance of immunosuppression. Delayed graft function was observed in 30.6% patients and 14% had biopsy proven acute rejection. Over mean follow-up of 2.35±1.24 years, patient and graft survival rates were 77.5% and 89.3% with mean SCr of 1.40±0.36 mg/dl. DDOT has acceptable graft/patient survival over 4 years follow-up and should be encouraged in view of organ shortage. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

28. Mesangial proliferative glomerulonephritis with acute tubule interstitial nephritis leading to acute kidney injury in influenza A (H1N1) infection.

Author

Kute, V. B., Vanikar, A. V., Shah, P. R., Gumber, M. R., Patel, H. V., and Trivedi, H. L.

Subjects
INFLUENZA complications, INTERSTITIAL nephritis, STEROID drugs, GLOMERULONEPHRITIS, OSELTAMIVIR, BLOOD testing, DIALYSIS (Chemistry), DRINKING (Physiology), MICROBIAL sensitivity tests, NEEDLE biopsy, PHYSICAL diagnosis, ULTRASONIC imaging, SYMPTOMS, INFLUENZA A virus, H1N1 subtype, DISEASE risk factors, THERAPEUTICS
Abstract

Respiratory complications and renal failure are the leading causes for morbidity and mortality due to influenza (H1N1) virus infection. There has been limited information on histopathology of H1N1 influenza-related acute kidney injury (AKI). We describe AKI with H1N1 infection in a 52-year-old female. Renal biopsy showed mesangial proliferative glomerulonephritis with acute tubule interstitial nephritis. Her condition improved rapidly with oseltamivir, fluid replacement, steroid and dialysis. Our case suggests that H1N1 infection may have a causative link to the development of mesangial proliferative glomerulonephritis with acute tubulointerstitial nephritis. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

29. Successful three.way kidney paired donation transplantation: The first Indian report.

Author

Kute, V. B., Gumber, M. R., Shah, P. R., Patel, H. V., Vanikar, A. V., Modi, P. R., Shah, V. R., and Trivedi, H. L.

Subjects
*KIDNEY transplantation, *ACADEMIC medical centers, *ORGAN donors, *SPOUSES, *DESCRIPTIVE statistics
Abstract

Providing transplantation opportunities for patients with incompatible live donors through kidney paired donation (KPD) is an important strategy for easing the crisis in organ availability. KPD is can overcome the barriers when the only living potential donors are deemed unsuitable owing to an incompatibility of blood type, of human leukocyte antigen cross-match, or both. In KPD, the incompatibility problems with two donor recipient pairs can be solved by exchanging donors. In the absence of well-organized deceased donor program, or transplantation with desensitization protocol and ABO incompatible transplantation, living donor KPD promises hope to the growing number of patients suffering from end-stage renal disease in India. We report our first successful three-way KPD transplantation from India. In an era of organ shortage, this approach is relevant to encourage wider participation from KPD donors and transplant centers to prevent commercial transplantation. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

30. Post-transplant infections.

Author

Shah, P. R., Kute, V. B., Gumber, M. R., Patel, H. V., Vanikar, A. V., Trivedi, H. L., and Jha, V.

Subjects
INFECTION prevention, KIDNEY transplantation, TRANSPLANTATION of organs, tissues, etc.
Abstract

A letter to the editor is presented in response to the article "Post transplant infections: An ounce of prevention," by V. Jha published in December 2012 issue.

Published
2012
Full Text
View/download PDF

32. Hemodialysis through persistent left superior vena cava.

Author

Kute, V. B., Vanikar, A. V., Gumber, M. R., Shah, P. R., Goplani, K. R., and Trivedi, H. L.

Subjects
CATHETERIZATION, CHRONIC kidney failure, HEMODIALYSIS, VENA cava superior
Abstract

We report a case of end stage renal disease patient who displayed a persistent left superior vena cava (PLSVC) after placement of hemodialysis (HD) catheter through left internal jugular vein, as revealed by routine post-procedure X-ray chest. The diagnosis of PLSVC was confirmed by arterial blood gas, two-dimensional echocardiography, computed tomography thorax and angiographic examination. This anomaly is rather rare; few studies on safety of PLSVC for HD have been reported. The catheter was uneventfully used for HD for 2 months with careful continuous monitoring and removed after arteriovenous fistula was successfully cannulated. Physicians who place HD catheters in the left jugular/subclavian vein should be aware of the existence of PLSVC. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

33. Successful renal transplantation from a deceased donor who died of bacterial meningitis.

Author

Kute, V. B., Vanikar, A. V., Patel, H. V., Gumber, M. R., Shah, P. R., Modi, P. R., and Trivedi, H. L.

Subjects
BACTERIAL diseases, BLOOD testing, DIAGNOSTIC imaging, KIDNEY transplantation, ORGAN donors, URINALYSIS, SOCIAL services case management, ANTIBIOTIC prophylaxis, BACTERIAL meningitis
Abstract

A letter to the editor is presented discussing two successful and uneventful renal transplants and a liver transplant from a deceased 12-year-old girl who died from pyogenic meningitis and diabetic ketoacidosis.

Published
2014
Full Text
View/download PDF

34. Meningioma in long-term survivor after renal transplantation.

Author

Kute, V. B., Patel, H. V., Vanikar, A. V., Shah, P. R., Gumber, M. R., Balwani, M. R., and Trivedi, H. L.

Subjects
KIDNEY transplantation, BIOPSY, BLOOD testing, ENZYME-linked immunosorbent assay, MAGNETIC resonance imaging, POLYMERASE chain reaction, MENINGIOMA, IMMUNOCOMPROMISED patients, DIAGNOSIS, HISTORY, DISEASE risk factors
Abstract

The article describes a case of meningioma in a 50-year-old man who received a renal allograft from his brother. The patient developed focal followed by generalized seizures twelve years after renal transplantation (RTx). Magnetic resonance imaging (MRI) results indicated a homogenously enhancing extra-axial space occupying lesion involving the right parietal parasagital region adjacent to the superior sagittal sinus, which could be meningioma.

Published
2013
Full Text
View/download PDF

35. Benzene hexachloride poisoning with rhabdomyolysis and acute kidney injury.

Author

Shah, P. R., Kute, V. B., Gumber, M. R., Patel, H. V., Patel, M. P., Yadav, D. K., Vanikar, A. V., and Trivedi, H. L.

Subjects
BLOOD testing, BLOOD gases analysis, CHRONIC kidney failure, PHYSICAL diagnosis, POISONING, RHABDOMYOLYSIS, URINALYSIS, OXIDATIVE stress, BENZENE derivatives
Abstract

The article discusses a case study of 21‑year‑old male who was admitted to the hospital for evaluation and management of renal failure and was presented with oliguria, dark color of urine, pedal edema, and muscular pain since 2 days. It mentions that a clinical diagnosis of gamma benzene hexachloride (BHC)‑induced rhabdomyolysis leading to acute kidney injury (AKI) was made.

Published
2013
Full Text
View/download PDF

36. Nephrotic syndrome after thymectomy for myasthenia gravis.

Author

Kute, V. B., Shah, P. R., Shrimali, J. D., Gumber, M. R., Patel, H. V., Vanikar, A. V., and Triveldi, H. L.

Subjects
MYASTHENIA gravis, THYMUS surgery, BIOPSY, BLOOD testing, KIDNEYS, NEPHROTIC syndrome, PARANEOPLASTIC syndromes, THYMUS tumors, ULTRASONIC imaging, PREDNISOLONE, DIAGNOSIS
Abstract

The author discusses a case study of a 28‑year‑old man was admitted for evaluation of anasarca, with the medical history of biopsy‑proven benign thymoma and myasthenia gravis (MG). He states that imaging of mediastinum showed thymic tumor. He also mentions that case reports of thymoma with nephrotic syndrome as a systemic manifestation are very rarely encountered.

Published
2013
Full Text
View/download PDF

37. Plasmodium vivax malaria presenting as hemolytic uremic syndrome.

Author

Patel, M. P., Kute, V. B., Gumber, M. R., Gera, D. N., Shah, P. R., Patel, H. V., Trivedi, H.L., and Vanikar, A. V.

Subjects
MALARIA diagnosis, BIOPSY, BLOOD testing, DIFFERENTIAL diagnosis, HEMOLYTIC-uremic syndrome, KIDNEYS
Abstract

The article discusses a case study of a 20‑year‑old female who presented with fever, chills, rigors followed by oliguria for 4 days. It also discusses plasmodium vivax malaria presenting as hemolytic uremic syndrome. Factors like volume depletion, intra‑vascular hemolysis, and sepsis along with hypercatabolic state can lead to acute renal failure in vivax malaria and usually leads to acute tubular necrosis with renal recovery over 3‑4 weeks depending on early diagnosis and treatment.

Published
2013
Full Text
View/download PDF

38. Authors' reply.

Author

Vanikar, A V, Kanodia, K V, Patel, R D, Suthar, K S, Patel, H V, Gumber, M R, and Trivedi, H L

Published
2013

39. Successful renal transplantation from a brain-dead deceased donor who died from snakebite: a case report.

Author

Kute VB, Vanikar AV, Patel HV, Gumber MR, Shah PR, Engineer DP, Modi PR, Rizvi SJ, and Trivedi HL

Subjects
Adult, Female, Humans, Kidney Transplantation, Male, Treatment Outcome, Brain Death, Cause of Death, Snake Bites, Tissue Donors
Abstract

Even though India is the country with the highest annual number of deaths (50,000) from snakebite, there is contradictory evidence regarding acceptance of deceased donors (DD) who died from this cause. We present 2 successful renal transplantations (RTx) from a brain-dead DD who died from a neurotoxic snakebite without manifestations of a viper bite. We accepted the donor as he exhibited no evidence of hematoxic snakebite. Rather the findings were consistent with a neurotoxic bite (probably krait), which can cause hypoxic brain injury. Both recipients established good diuresis intraoperatively and did not require hemodialysis. The patients were discharged with good diuresis and normal serum creatinines. After 3-month follow-up, both recipients show normal graft function. According to our experience of favorable RTx outcomes from a brain-dead DD who died from neurotoxic snakebite may expand the donor pool., (Copyright © 2013 Elsevier Inc. All rights reserved.)

Published
2013
Full Text
View/download PDF

40. Outcome of renal transplantation from deceased donors after cardiac death: a single-center experience from a developing country.

Author

Kute VB, Vanikar AV, Shah PR, Gumber MR, Patel HV, Modi PR, Rizvi SJ, Shah VR, and Trivedi HL

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Communicable Diseases etiology, Delayed Graft Function etiology, Female, Graft Rejection immunology, Graft Rejection prevention & control, Graft Survival drug effects, Humans, Immunosuppressive Agents therapeutic use, India, Kaplan-Meier Estimate, Male, Middle Aged, Risk Factors, Time Factors, Treatment Outcome, Young Adult, Developing Countries, Kidney Transplantation adverse effects, Kidney Transplantation mortality, Tissue Donors supply & distribution
Abstract

Background: Limited information is available in the literature about the use of organs from donation after cardiac death (DCD) renal transplantation (RTx) from a developing country., Material and Methods: We report RTx outcome between DCD donors ≥70 years (Group 1; n = 14; mean age, 75.7 ± 5.81) and DCD donors <70 years (Group 2; n = l9; mean age, 51.7 ± 10.1) between January 1999 and January 2012. The mean age of recipients was 39.5 ± 14.7 years, 24 of whom were males. The mean donor age was 61.9 ± 14.6 years, 21 of whom were males. All recipients received single-dose thymoglobulin induction followed by immunosuppression with a steroid, a calcineurin inhibitor, and mycophenolate mofetil or azathioprine. Statistical analysis used chi-square test and unpaired Student t test. Kaplan-Meier curves were used for survival analysis., Results: Over a mean follow-up of 3.21 ± 3.46 years, one-, five-, and ten-year, patient survival rates were 77%, 67.4%, and 67.4%, respectively, and death-censored graft survival rates were 85.7% for one, five, and ten years. Delayed graft function (DGF) was observed in 36.4% (n = 12) with 12.1% (n = 4) biopsy-proven acute rejection (BPAR). Patient survival (P = .27), graft survival (P = .20), DGF (P = .51), and BPAR (P = .74) were similar in 2 groups. A total of 27.2% (n = 9) of patients died, mainly due to infections (n = 5)., Conclusion: Given the widespread organ shortage, outcomes of controlled DCD renal transplantation has a potential to expand the donor pool and shorten the waiting list for RTx, encouraging the use of this approach even in low-income countries., (Copyright © 2013 Elsevier Inc. All rights reserved.)

Published
2013
Full Text
View/download PDF

42. Post-renal transplant cytomegalovirus infection: study of risk factors.

Author

Kute VB, Vanikar AV, Shah PR, Gumber MR, Patel HV, Godara SM, Munjappa BC, Sainaresh VV, Engineer DP, Jain SH, Modi PR, Shah VR, Trivedi VB, and Trivedi HL

Subjects
Adult, Antiviral Agents therapeutic use, Cytomegalovirus genetics, Cytomegalovirus Infections drug therapy, Cytomegalovirus Infections prevention & control, DNA, Viral blood, Enzyme-Linked Immunosorbent Assay, Female, Ganciclovir therapeutic use, Graft Rejection, Humans, Immunosuppressive Agents administration & dosage, Male, Middle Aged, Risk Factors, Cytomegalovirus Infections etiology, Kidney Transplantation adverse effects
Abstract

Objectives: Cytomegalovirus (CMV) is a common opportunistic infection following renal transplantation (RTx). It responds promptly to antiviral treatment. The mortality rate reaches 90% if untreated. Identification of risk factors helps in the early diagnosis of CMV. We studied demographic features, risk factors, and outcomes associated with CMV infection in RTx recipients despite ganciclovir prophylaxis., Materials and Methods: We reviewed 720 RTx recipients between 2007 and 2009. We examined the serostatus of the donor and recipient before transplantation using an enzyme-linked immunosorbent assay, and diagnosed CMV infections in recipients by CMV DNA detection with a polymerase chain reaction., Results: A total of 42 of 750 (5.6%) patients were identified to display CMV infection (69.1%) or disease (30.9%). Their mean age was 34 ± 13.5 years, with 80.9% men. CMV serologic status was D+/R- in 21.4% and D+/R+ in 59.5% patients. Fever, malaise (76.2%), and leukopenia (52.3%) were the commonest presenting symptoms; diabetes (30.9%) and hepatitis C virus (28.6%) the commonest comorbid conditions. Risk factors were triple drug immunosuppression (47.6%), antithymocyte globulin ATG induction (54.8%), and a rejection episode (26.1%) and methylprednisolone (76.2%) which were more common in CMV disease than infection. Mean CMV DNA at diagnosis was 78,803; 71.2% patients developed CMV within 6 months posttransplantation, the majority occurring after 3 months. With a mean follow-up of 4 ± 1.9 years, patient and graft survival rates were 85.7% and 81% with a mean serum creatinine value of 1.83 ± 12 mg/dL., Conclusions: Universal CMV prophylaxis was associated with a low incidence (5.6%) and mild form of CMV disease among our patients., (Copyright © 2012 Elsevier Inc. All rights reserved.)

Published
2012
Full Text
View/download PDF

43. World kidney day 2010: medical aspects of 10 live-donor renal transplantations in a single center from a developing country.

Author

Shah PR, Modi PR, Kute VB, Vanikar AV, Patel HV, Gumber MR, Shah VR, and Trivedi HL

Subjects
Adult, Biomarkers blood, Creatinine blood, Female, Graft Rejection blood, Graft Rejection etiology, Graft Rejection mortality, Graft Rejection prevention & control, Graft Survival, HLA Antigens immunology, Histocompatibility, Histocompatibility Testing, Humans, Immunosuppressive Agents therapeutic use, India, Male, Middle Aged, Time Factors, Treatment Outcome, Developing Countries, Global Health, Health Promotion, Kidney Failure, Chronic therapy, Kidney Transplantation adverse effects, Kidney Transplantation immunology, Kidney Transplantation mortality, Living Donors
Abstract

Background: World Kidney Day (WKD) has become the most widely celebrated event associated with kidney disease in the world and the most successful effort to raise awareness among both the general public and government health officials about the dangers of kidney disease. We celebrated WKD 2010 in a unique way by performing 10 live-donor renal transplantations (RTx) on March 11, 2010., Patients and Methods: We report a single-center experience on RTx vis-à-vis patient/graft survival, graft function in terms of serum creatinine (SCr) level, and rejection episodes in 10 live-donor RTx performed on WKD. Recipient diseases leading to end-stage renal disease (ESRD) were chronic glomerulonephritis (60%), benign nephrosclerosis (20%), and chronic interstitial nephritis (20%). Mean recipient age was 35 ± 8.7 years. Nine recipients were males. Mean donor age was 37 ± 8.7 years, Nine donors were females. Donors were spouse (n = 6), mother (n = 2), sister (n = 1), and extended family member (n = 1), with mean HLA match 1.8 ± 1.48. All patients received steroids, calcinueurin inhibitors, and mycophenolate mofetil/azathioprime for maintenance immunosuppression., Results: During a mean follow-up time of 18 months, patient and graft survival rates were 90% and 90%, respectively, with a mean SCr level of 1.21 mg/dL; 20% had biopsy-proven acute rejection. One patient died due to infection after antirejection therapy., Conclusion: RTx has acceptable graft and patient survival. RTx is the best cost-effective therapeutic modality for patients suffering from ESRD and should be encouraged in view of organ shortage on events such as WKD. To our knowledge, this is the first report from a developing country on 10 successful RTx on WKD., (Copyright © 2012 Elsevier Inc. All rights reserved.)

Published
2012
Full Text
View/download PDF

44. Abrogation of antibodies improves outcome of renal transplantation.

Author

Trivedi HL, Vanikar AV, Gumber MR, Patel HV, Shah PR, and Kute VB

Subjects
Adult, Biomarkers blood, Biopsy, Blood Transfusion, Boronic Acids therapeutic use, Bortezomib, Creatinine blood, Female, Graft Rejection blood, Graft Rejection immunology, Hematopoietic Stem Cell Transplantation, Histocompatibility Testing, Humans, Immunosuppressive Agents therapeutic use, India, Living Donors, Lymphatic Irradiation, Male, Mesenchymal Stem Cell Transplantation, Pyrazines therapeutic use, T-Lymphocytes immunology, Time Factors, Treatment Outcome, Young Adult, Clonal Deletion, Graft Rejection prevention & control, Graft Survival, HLA Antigens immunology, Immunization methods, Immunosuppression Therapy methods, Isoantibodies blood, Kidney Transplantation immunology
Abstract

Introduction: Antibodies are known to cause rejection and therefore are detrimental to graft survival. We describe two protocols of clonal stimulation deletion (CSD) pretransplant followed by grafting with no conventional immunosuppression (IS)., Methods: CSD was employed in 54 patients of mean age, 28.7 years and mean human leukocyte antigen A/B/DR match, 3.25. The two protocols both employed stimulation with donor-specific transfusions and stem cells with deletion using total lymphoid irradiation in group 1 (n = 29) or bortezomib in group 2 (n = 25). Other adjuvants in both protocols were cyclophosphamide, rabbit antithymocyte globulin, and rituximab. Stimulation and deletion were monitored by lymphocyte crossmatches and detection of donor-specific antibodies (DSA). Posttransplant monitoring included serum creatinine (SCr) measurements and antibody detection at regular intervals. Graft biopsy performed in the event of dysfunction was managed by standard guidelines. Rescue IS was initiated upon a rise in SCr or DSA., Results: Mean follow-up in group 1 is 3.28 years and 2.11 years in group 2. There was 100% graft and patient survivals in both cohorts with 23 patients without IS and stable graft function with an SCr of 1.3 mg/dL. All acute rejection episodes, which occurred among 24.1% of group 1 and 20% of group 2, were rescued with therapy evolving as a SCr of 1.6 to 1.9. The majority of rejections were antibody-combined with T-cell-mediated responses. We did not observe untoward effects of the protocol., Conclusion: Abrogation of antibodies improved renal transplant outcomes., (Copyright © 2012 Elsevier Inc. All rights reserved.)

Published
2012
Full Text
View/download PDF

45. Clinical outcome of renal transplantation in end-stage renal disease patients with positive pretransplantation hepatitis B surface antigen.

Author

Patel HV, Kute VB, Vanikar AV, Shah PR, Gumber MR, Jain SH, Engineer DP, Ghelani GH, and Trivedi HL

Subjects
Adult, Biomarkers blood, Female, Graft Rejection etiology, Graft Survival, Hepatitis B diagnosis, Hepatitis B mortality, Humans, Immunosuppressive Agents therapeutic use, India, Kidney Failure, Chronic complications, Kidney Failure, Chronic mortality, Male, Middle Aged, Retrospective Studies, Risk Assessment, Risk Factors, Survival Analysis, Time Factors, Treatment Outcome, Young Adult, Hepatitis B complications, Hepatitis B Surface Antigens blood, Kidney Failure, Chronic surgery, Kidney Transplantation adverse effects, Kidney Transplantation mortality
Abstract

Background: Renal transplantation (RTx) is the best therapeutic modality for patient suffering from end-stage renal disease (ESRD) with positive pretransplantation hepatitis B surface antigen (HbsAg). We report 11 years of single-center experience on RTx vis-à-vis patient/graft survival, graft function in terms of serum creatinine (SCr), and rejection episodes in 35 ESRD patients with pretransplantation HbsAg positivity., Patients and Methods: Thirty-five ESRD patients with pretransplantation HbsAg positivity underwent RTx at our center between 2000 and 2010. Mean recipient age was 36.06 ± 12.22 years; 30 were males and 5 were females. Mean donor age was 43.51 ± 13.63 years; 13 were males and 22 were females. The majority of donors were parents (31.42%) and spouses (22.85%). Mean HLA match was 2 ± 1.37. The most common recipient diseases leading to ESRD were chronic glomerulonephritis (51%) and diabetes (17.5%). Posttransplantation immunosuppression consisted of a calcineurin inhibitor-based regimen., Results: Over mean follow-up of 6.16 ± 3.69 years, patient and graft survival rates were 71.42% and 71.42%, respectively, with mean SCr of 1.92 ± 0.62 mg% with 20% biopsy-proven acute rejection episodes. In total, 10 (28.57%) patients were lost, mainly to infections., Conclusion: RTx for ESRD with pretransplantation HbsAg positivity has acceptable graft function and patient/graft survival over 11 years follow-up and should be encouraged., (Copyright © 2012 Elsevier Inc. All rights reserved.)

Published
2012
Full Text
View/download PDF

46. Outcome of renal transplantation in Alport's syndrome: a single-center experience.

Author

Gumber MR, Kute VB, Goplani KR, Vanikar AV, Shah PR, Patel HV, and Trivedi HL

Subjects
Adolescent, Adult, Anti-Glomerular Basement Membrane Disease diagnosis, Anti-Glomerular Basement Membrane Disease etiology, Anti-Glomerular Basement Membrane Disease therapy, Biomarkers blood, Biopsy, Creatinine blood, Female, Graft Rejection diagnosis, Graft Rejection etiology, Graft Rejection therapy, Graft Survival, Humans, Immunosuppressive Agents adverse effects, India, Kaplan-Meier Estimate, Living Donors, Male, Middle Aged, Nephritis, Hereditary mortality, Reoperation, Risk Assessment, Risk Factors, Time Factors, Treatment Outcome, Young Adult, Kidney Transplantation adverse effects, Kidney Transplantation mortality, Nephritis, Hereditary surgery
Abstract

Background: Anti-glomerular basement membrane (anti-GBM) nephritis post-renal transplantation (RTx) is known to cause graft loss in Alport's syndrome (AS). We evaluated the results of RTx in AS patients vis à vis patient and graft survivals, incidence of anti-GBM nephritis, and causes of graft failure., Materials and Methods: Between 1993 and 2009 we performed 31 RTx on AS patients (28 males and three females) of overall mean age of 22 ± 7.9 years from six deceased and 27 living donors. Two patients underwent second RTx., Results: Over a follow-up of 1, 3, 5, and 10 years, the mean serum creatinines (mg/dL) were 1.51 ± 0.52, 1.59 ± 0.26, 1.61 ± 0.30, and 1.63 ± 0.32, respectively. Patient survivals at 1, 5, and 10 years were 89.71%, 81.32% and 81.32% with graft survival for all periods of 81.2%. Twenty-one percent experienced biopsy-proven acute rejection episodes. Graft failures were due to anti-GBM nephritis in 12.2% (n = 4), chronic allograft nephropathy in 3.2% (n = 1), and acute rejection or cyclosporine toxicity 3.2% (n = 1 each). The mean duration to graft loss was 4.9 ± 2.4 months., Conclusion: Graft and patient survivals were acceptable among transplant recipients with AS despite the risk of anti-GBM nephritis., (Copyright © 2012 Elsevier Inc. All rights reserved.)

Published
2012
Full Text
View/download PDF

47. Lupus nephritis associated with CD20+ B-cell NHL.

Author

Gumber MR, Kute VB, Goplani KR, Shah PR, Vanikar AV, and Trivedi HL

Subjects
Antibodies, Monoclonal, Murine-Derived therapeutic use, Antineoplastic Agents therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biopsy, Epstein-Barr Virus Infections drug therapy, Epstein-Barr Virus Infections pathology, Herpesvirus 4, Human, Humans, Immunohistochemistry, Lupus Nephritis complications, Lupus Nephritis drug therapy, Lymphoma, Large B-Cell, Diffuse complications, Lymphoma, Large B-Cell, Diffuse drug therapy, Male, Middle Aged, Rituximab, Treatment Outcome, Epstein-Barr Virus Infections complications, Lupus Nephritis pathology, Lymphoma, Large B-Cell, Diffuse pathology
Abstract

The combination of NHL and documented malignancy-associated glomerulonephritis is uncommon. Also, no single renal pathological entity is consistently found in patients with NHL. Epstein-Barr virus (EBV) infection may manifest as systemic lupus erythematosus (SLE) and/or diffuse large cell lymphoma (DLBCL) in a genetically/ immunologically susceptible individual with defective cytotoxic T-cell response against EBV. We describe lupus nephritis in a 45 years old male suffering from untreated NHL. CD20+ DLBCL was demonstrated by immunohistochemistry of the neck lymph node (LN) biopsy performed for generalized lymphadenopathy. Renal biopsy revealed class V + IV lupus nephritis. Serology demonstrated EBV infection. Complete clinical remission of both SLE and DLBCL was achieved post-therapy with six-cycle rituximab, cyclophosphamide, vincristin, adriablastin, methylprednisolone (R-CHOP) regime. This case report demonstrated the complex relationships between NHL, SLE, EBV and membranous glomerulonephritis. The presented case is remarkable not only because of the rare association of SLE and DLBCL, but also because of its successful treatment with R-CHOP.

Published
2011

48. Effect of post-transplant weight at one year on renal allograft function.

Author

Patel HV, Goplani KR, Vanikar AV, Trivedi HL, Gumber MR, Jain SH, Kute VB, Gireesh MS, and Shah PR

Subjects
Adult, Female, Follow-Up Studies, Humans, Kidney Failure, Chronic complications, Male, Obesity physiopathology, Postoperative Period, Risk Factors, Time Factors, Transplantation, Homologous, Body Weight, Graft Survival physiology, Kidney Failure, Chronic surgery, Kidney Transplantation physiology, Obesity complications
Published
2011

49. Operational tolerance in living-related renal transplantation: a single-center experience.

Author

Vanikar AV, Goplani KR, Feroz A, Kanodia KV, Patel RD, Suthar KS, Patel HV, Gumber MR, Shah PR, and Trivedi HL

Subjects
Adolescent, Adult, Aged, Child, Chimera, Female, Flow Cytometry, Graft Rejection, Graft Survival, Humans, Male, Middle Aged, Stem Cell Transplantation, Survival Analysis, Transplantation Conditioning, Young Adult, Family, Immune Tolerance, Kidney Transplantation, Living Donors
Abstract

Introduction: Various methods have been tried to induce operational tolerance in organ transplantation. We present a single-center experience using 6 tolerance induction protocols (TIP) in living-related renal transplantation., Methods: We evaluated 6 TIP protocols: (1) peripheral blood stem cells employed (n = 38); (2) midified the protocol by portal infusion (n = 292); (3) the second protocol plus TIP+DST+BM+intrathymic and intramarrow infusion plus low-dose, nonmyeloablative conditioning employed (n = 174), (4) the third protocol of TIP plus cultured hematopoietic stem cells (HSC) with target-specific irradiation (n = 290); (5) TIP 4 plus thymus, intramarrow infusion, and target-specific irradiation converted to total lymphoid irradiation (TLI) (n = 366); and (6) TIP 5 plus bortzomib-TLI (n = 165). Patient/donor demographics were comparable., Results: We evaluated patient and graft survival, rejection episodes, recurrence, drug toxicity, and chimerism revealed; groups 4 and 5 showed better survival, graft function, chimerism, and decreased rejection episodes compared with previous protocols. Serum creatinine (mg/dL) at 1 year was 1.5, 1.39, 1.5, 1.51, 1.46, and 1.41, and at 5 years, 1.69, 1.72, 1.82 and 1.59, in groups 1-6, respectively. Chronic rejection episodes were 10.5%, 14.1%, 10.4%, 9.3%, 3.5%, 1.7%, and 1.8% respectively. Patient survival of groups 1, 2, and 3 at 1, 5, and 10 years was 86.5%, 56.8%, and 40.1%; 89.4%, 69.1%, and 56.4%; and 89.6%, 67.7%, and 64.6%, respectively; of group 4 for 1 and 5 years was 92.4% and 81.8%; for groups 5 and 6 for 1 year was 94% and 96.3%, respectively. The death-censored graft survival of groups 1, 2, and 3 at 1, 5, and 10 years was 91.9%, 70.3%, and 64.7%; 89%, 66%, and 57.6%; and 86.7%, 67%, and 42.5%, respectively. In group 4 for 1 and 5 years was 87.9% and 74.7%; and for groups 5 and 6 for 1 year was 94% and 96.5%, respectively., Conclusion: TIP results showed improved graft/patient survivals, minimum immunosuppression, and fewer rejection episodes and recurrence., (Copyright © 2011 Elsevier Inc. All rights reserved.)

Published
2011
Full Text
View/download PDF

50. Transplantation with kidney paired donation to increase the donor pool: a single-center experience.

Author

Gumber MR, Kute VB, Goplani KR, Shah PR, Patel HV, Vanikar AV, Pandya TP, and Trivedi HL

Subjects
Feasibility Studies, Graft Survival, Humans, Kidney Transplantation, Tissue Donors, Tissue and Organ Procurement
Abstract

Background: A living either related or unrelated donor transplant leads to a better outcome in terms of patient and graft survivals compared with one from a deceased donor. Desensitization protocols are expensive and labor intensive. The use of unrelated living donors has the greatest potential to increase the number of donors in the future, when no willing living donor is available due to blood group and/or human leukocyte antigen incompatibility. Herein, we have reported our results with a living donor exchange program., Aims: To determine the feasibility and effectiveness of kidney paired donation (KPD) to manage patients with incompatible donors as well as present patient and graft survivals, serum creatinine (S.Cr) levels, and rejection episodes., Results: Between June 2000 and December 2009, we performed KPD transplants in 36 recipients to avoid blood group incompatibility (n = 28) or to avoid a positive crossmatch (n = 8). At a median follow-up of 27.7 months (range, 5.83-119.8). The patient survival rate was 88.9% and the graft survival rate was 94.4%. Four patients developed acute cellular rejection episodes (11.1%) and 3 (8.3%) acute antibody-mediated rejection. At 1, 3, and 5 years, the mean S.Cr values were 1.42 ± 0.28 mg% (n = 28) 1.61 ± 0.51 (n = 22) and 1.24 ± 0.15 (n = 8), respectively., Conclusions: The incidence of acute rejection episodes and patient/graft survivals were acceptable in our KPD program. The use of unrelated living donors has great potential to increase the number of donors in the future; a national KPD program should be encouraged in India., (Copyright © 2011 Elsevier Inc. All rights reserved.)

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results